Abdominal or central obesity is a greater risk factor compared to overall obesity: Indian Minister

He explained that central obesity is an independent risk factor, separate from general obesity, and can significantly increase the likelihood of metabolic disorders.

He was speaking at a ceremony where he released a comprehensive cardiology textbook titled “Advances in Obesity and Lipid Management in CVD.”

Dr. Singh highlighted that central obesity—even in apparently non-obese individuals—can predispose them to a wide range of metabolic conditions, including diabetes, hypertension, cardiovascular diseases, fatty liver, and lipid disorders.

Referring to India’s distinct metabolic profile, he noted that while overall obesity is increasing among both men and women, abdominal obesity remains disproportionately high and is a key independent determinant of cardiometabolic risk. The presence of visceral fat around the abdomen, even without generalized obesity, has serious clinical implications and requires early detection and targeted intervention.

Describing the publication as timely and relevant, he said it aligns with the national priority of addressing the growing burden of obesity, as emphasized by Prime Minister Narendra Modi, who has called for greater public awareness and lifestyle changes, including reduced oil consumption and healthier dietary habits.

He added that the initiative aligns with the broader vision of “Viksit Bharat, Swasth Bharat, and Obesity-Free Bharat.”

Highlighting evolving clinical evidence, the Minister pointed to the growing link between abdominal fat and conditions such as fatty liver disease, insulin resistance, and early-onset cardiovascular complications. He noted that rising metabolic disorders, including type-2 diabetes and cardiac events among younger populations, reflect changing lifestyles, dietary patterns, and reduced physical activity.

Dr. Singh also stressed the importance of balanced health practices, cautioning that excessive or unscientific fitness routines, including overexertion without proper preparation or rest, can also pose health risks. He emphasized the need for sustained lifestyle discipline, adequate sleep, and scientifically guided preventive care.

The textbook, edited by noted cardiologist Dr. H.K. Chopra, compiles insights from over 300 contributors from India and abroad. It marks a shift from conventional risk-factor-based approaches to precision prevention, integrating advances in metabolic therapies, lipid management, digital health, and AI-enabled clinical decision-making.

It also covers emerging treatments such as GLP-1 receptor agonists including Semaglutide and Tirzepatide, as well as lipid-lowering therapies like statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran, apheresis, and gene-based interventions—advances expected to significantly improve cardiovascular outcomes and reduce disease burden.

In his foreword, Dr. Singh described obesity and dyslipidemia as major public health challenges contributing to rising cardiovascular morbidity and mortality in India and globally. He emphasized the need for stronger awareness, preventive strategies, and evidence-based clinical practices.

Referring to projections indicating a sharp rise in obesity in India by 2050, he called for enhanced awareness, early screening, and preventive healthcare measures to reduce long-term health and economic risks.

The book comprises 23 sections and 172 chapters, serving as a comprehensive, evidence-based clinical resource bridging research and bedside care. It is expected to contribute significantly to capacity building, clinical excellence, and improved patient outcomes.

Dr. Singh also expressed appreciation to Dr. H.K. Chopra and the editorial team for their academic leadership in bringing together global expertise into a single authoritative volume. Leading cardiologists including Dr. Viveka Kumar, Dr. Praveen Chandra, Dr. J.P.S. Sawhney, Dr. Mona Bhatia, Dr. Anu Grover, Shrikant Bhatia, and Anand Kumar were present at the event.